Compared with the model group, the TBC intervention group was primarily involved in immunomodulation (antigen processing and presentation, intestinal immune network for IgA production), immune cell differentiation (Th1 and Th2 cell differentiation, Th17 cell differentiation, hematopoietic cell lineage), type I diabetes mellitus, and immune-related diseases (human T-cell leukemia virus 1 infection, systemic lupus erythematosus, rheumatoid arthritis, and autoimmune thyroid disease) (Figure 8H). Here, CD79A is linked to type 1 diabetes mellitus.